HC Wainwright Issues Positive Forecast for Evotec (NASDAQ:EVO) Stock Price

Evotec (NASDAQ:EVO) had its price objective boosted by HC Wainwright from $4.00 to $5.00 in a report released on Friday,Benzinga reports. The firm currently has a buy rating on the stock.

Several other brokerages have also issued reports on EVO. Weiss Ratings lowered Evotec from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Tuesday, August 25th. Berenberg Bank downgraded shares of Evotec from a “buy” rating to a “hold” rating in a report on Thursday, July 16th. Finally, TD Cowen lowered shares of Evotec from a “buy” rating to a “hold” rating and set a $2.00 price target on the stock. in a research note on Wednesday, July 15th. One analyst has rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, Evotec currently has a consensus rating of “Hold” and a consensus target price of $3.50.

Evotec Trading Down 4.8%

EVO stock traded down $0.09 during midday trading on Friday, hitting $1.69. 66,975 shares of the company’s stock were exchanged, compared to its average volume of 94,361. Evotec has a one year low of $1.33 and a one year high of $3.87. The company has a debt-to-equity ratio of 0.62, a quick ratio of 2.21 and a current ratio of 2.33. The stock’s fifty day moving average price is $1.62 and its 200-day moving average price is $2.48.

Hedge Funds Weigh In On Evotec

An institutional investor recently raised its stake in Evotec stock. WCM Investment Management LLC lifted its holdings in Evotec AG (NASDAQ:EVO) by 12.1% during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 627,260 shares of the company’s stock after purchasing an additional 67,917 shares during the quarter. WCM Investment Management LLC owned 0.18% of Evotec worth $1,480,000 as of its most recent SEC filing. Institutional investors own 5.81% of the company’s stock.

Evotec News Summary

Here are the key news stories impacting Evotec this week:

• Positive Sentiment: Third-quarter results beat analyst expectations: Evotec reported an adjusted EBITDA loss of €1.6 million, while revenue exceeded the consensus estimate cited in reports. The company reaffirmed its 2026 outlook, and sales in its D&PD base business rose 24%. Evotec Q3 and nine-month results
• Positive Sentiment: Analyst sentiment includes a Buy rating from RBC Capital and HC Wainwright’s increase in its price target from $4 to $5, signaling potential upside in analysts’ view. RBC Capital rating HC Wainwright price target
• Neutral Sentiment: Evotec secured a manufacturing mandate from Vertex, which could support future business, though the available report does not quantify its financial contribution. Vertex manufacturing mandate
• Negative Sentiment: Nine-month revenue was lower year over year, and Evotec tempered and pushed back medium-term goals, including reducing its 2030 revenue target. That may weigh on investor confidence despite the quarterly improvement. Target changes and restructuring
• Negative Sentiment: Coverage of the Redmond expansion highlights a potential gap between added capacity and revenue generation, raising the risk that costs precede the benefits. Redmond expansion analysis

About Evotec

Evotec SE is a Germany-based biotechnology company that provides drug discovery and development services to pharmaceutical, biotechnology and academic research organizations. The company combines scientific expertise, proprietary technologies and integrated research platforms to identify and advance potential medicines across multiple therapeutic areas, including neuroscience, oncology, metabolic disease, infectious disease and inflammation.

Evotec’s activities span early-stage target identification, compound screening, medicinal chemistry, pharmacology, preclinical research and selected clinical development services.